Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935707 | 0.89 | MAPK14 (0.39) | MAPK14KIF11CFTRSLC40A1BRD4 | |
| SCHEMBL689712 | 0.87 | MAPK14 (0.51) | MAPK14 | |
| Hydrochloric Acid SCHEMBL1301953 | 0.85 | MAPK14 (0.50) | MAPK14 | |
| SCHEMBL692913 | 0.81 | MAPK14 (0.42) | MAPK14KIF11CFTRGPR35MEN1 | |
| SCHEMBL15086946 | 0.78 | CFTR (0.40) | MAPK14KIF11CFTRSLC40A1RAB9A | |
| SCHEMBL16106484 | 0.77 | CA2 (0.40) | MAPK14SLC22A12FFAR4 | |
| SCHEMBL19434662 | 0.77 | MAPK14 (0.44) | MAPK14 | |
| SCHEMBL689608 | 0.77 | L3MBTL1 (0.51) | CFTRALOX5APFEN1RAB9AL3MBTL1 | |
| SCHEMBL4034906 | 0.77 | MAPK14 (0.41) | MAPK14 | |
| SCHEMBL26906947 | 0.75 | KIF11 (0.57) | KIF11CFTRSLC22A12SLC40A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335657-B2 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2008-02-26 | — | — | US | claimed |
| US-20060235017-A1 | Cytokine Inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | US | claimed |
| US-7078419-B2 | N-aryl-7-(pyridin-4yl-methyl-, oxy-, thio-or amino-)indole-2-carbonamide derivatives, e.g., 7-(2,6-Dimethyl-pyridin-4-yloxy)-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide; treating chronic inflammatory diseases and anticoagulant or fibrinolytic therapy | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-07-18 | — | — | US | claimed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | claimed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946438-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8735579-B2 | Benzamides, production thereof, and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-6872726-B2 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-03-29 | — | — | US | disclosed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20040186114-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | US | disclosed |
| WO-2004050642-A1 | 1, 2, 3- TRIAZOLE AMIDE DERIVATIVES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20040102492-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004014870-A1 | FLUORINATED PHENYL-NAPHTHALENYL-UREA COMPOUNDS AS INHIBITORS OF CYTOKINES INVOLVED IN INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077647-A1 | Cytokine inhibitors, antiinflammatory agents | IL1B, IL1A, TNF | MAPK14 1398/4885KIF11 4744/4885CFTR 371/4885 |
| US-20050032797-A1 | Fluorinated di-aryl urea compounds | IL1B, MPO, IL1A | MAPK14 1915/4885KIF11 4676/4885CFTR 88/4885 |
| US-20040186114-A1 | Cytokine inhibitors | IL1A, IL1B, IL1R1 | MAPK14 2339/4885KIF11 4578/4885CFTR 652/4885 |
| US-20140187539-A1 | NOVEL BENZAMIDES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | HRH2, HRH1, HRH4 | MAPK14 2338/4885KIF11 3332/4885CFTR 38/4885 |
| US-20040102492-A1 | Cytokine inhibitors | IL1A, IL1B, IL1RN | MAPK14 1621/4885KIF11 4630/4885CFTR 370/4885 |
| US-20060235017-A1 | Cytokine Inhibitors | IL1B, IL1A, IL1R1 | MAPK14 2628/4885KIF11 4531/4885CFTR 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.